{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:52:42Z","timestamp":1782377562294,"version":"3.54.5"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"ACEPAIN Foundation"},{"name":"Ministerio de Ciencia e Innovaci\u00f3n and Agencia Estatal de Investigaci\u00f3n","award":["CPP2021-008597"],"award-info":[{"award-number":["CPP2021-008597"]}]},{"DOI":"10.13039\/501100011698","name":"Junta de Comunidades de Castilla-La Mancha","doi-asserted-by":"publisher","award":["SBPLY\/21\/180501\/000050"],"award-info":[{"award-number":["SBPLY\/21\/180501\/000050"]}],"id":[{"id":"10.13039\/501100011698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["10.13039\/50110001103"],"award-info":[{"award-number":["10.13039\/50110001103"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01399-9","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:41:04Z","timestamp":1782376864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines"],"prefix":"10.1007","volume":"27","author":[{"given":"Salma","family":"Mart\u00ednez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7328-6142","authenticated-orcid":false,"given":"Cristina","family":"Blasco-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1231-9252","authenticated-orcid":false,"given":"Sof\u00eda","family":"Blas-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1589-5399","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9250-9688","authenticated-orcid":false,"given":"Mar\u00eda del Mar","family":"Noblejas-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"1399_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-3-030-20301-6_4","volume-title":"Advances in Experimental Medicine and Biology","author":"M Fahad Ullah","year":"2019","unstructured":"Fahad Ullah M. Breast Cancer: Current Perspectives on the Disease Status. Advances in Experimental Medicine and Biology. Volume 1152. Cham: Springer; 2019. pp. 51\u201364. https:\/\/doi.org\/10.1007\/978-3-030-20301-6_4."},{"issue":"8","key":"1399_CR2","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy\u2019. Ann Oncol. 2016;27(8):1482\u201392. https:\/\/doi.org\/10.1093\/annonc\/mdw168.","journal-title":"Ann Oncol"},{"issue":"8","key":"1399_CR3","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/J.CELL.2023.01.040","volume":"186","author":"E Nolan","year":"2023","unstructured":"Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186(8):1708\u201328. https:\/\/doi.org\/10.1016\/J.CELL.2023.01.040.","journal-title":"Cell"},{"key":"1399_CR4","doi-asserted-by":"publisher","unstructured":"Abbott M, Ustoyev Y. Cancer and the Immune System: The History and Background of Immunotherapy. Semin Oncol Nurs. 2019;35(5). https:\/\/doi.org\/10.1016\/j.soncn.2019.08.002.","DOI":"10.1016\/j.soncn.2019.08.002"},{"key":"1399_CR5","doi-asserted-by":"publisher","unstructured":"Barzaman K, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84. https:\/\/doi.org\/10.1016\/j.intimp.2020.106535.","DOI":"10.1016\/j.intimp.2020.106535"},{"issue":"4","key":"1399_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/S10585-024-10300-7","volume":"41","author":"SP Leong","year":"2024","unstructured":"Leong SP. Immune responses and immunotherapeutic approaches in the treatment against cancer. Clin Exp Metastasis. 2024;41(4):473\u201393. https:\/\/doi.org\/10.1007\/S10585-024-10300-7","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"1399_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/S41573-018-0006-Z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175\u201396. https:\/\/doi.org\/10.1038\/S41573-018-0006-Z.","journal-title":"Nat Rev Drug Discov"},{"key":"1399_CR8","doi-asserted-by":"publisher","unstructured":"Puntambekar M, Shery N, Parokkaran I, Al-Hamas M. Predictive biomarkers in cancer immunotherapy: a narrative review. Sel Solid Tumors\u2019 Cureus. 2025;17(7). https:\/\/doi.org\/10.7759\/cureus.88647.","DOI":"10.7759\/cureus.88647"},{"key":"1399_CR9","doi-asserted-by":"publisher","unstructured":"Ribeiro R, Carvalho MJ, Goncalves J, Moreira JN. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. Front Mol Biosci. 2022;9(903065). https:\/\/doi.org\/10.3389\/fmolb.2022.903065.","DOI":"10.3389\/fmolb.2022.903065"},{"issue":"4","key":"1399_CR10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/biomedicines12040763","volume":"12","author":"A Ciarka","year":"2024","unstructured":"Ciarka A, Pi\u0105tek M, P\u0119ksa R, Kunc M, Senkus E Tumor-infiltrating lymphocytes (TILs) in breast cancer: prognostic and predictive significance across molecular subtypes. Biomedicines. 2024;12(4):763. https:\/\/doi.org\/10.3390\/biomedicines12040763","journal-title":"Biomedicines"},{"key":"1399_CR11","unstructured":"\u2018Definition of pathologic complete response - NCI Dictionary of Cancer Terms - NCI\u2019. Accessed: Apr. 20, 2026. [Online]. Available: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/pathologic-complete-response"},{"key":"1399_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","volume":"452","author":"W Di Yu","year":"2019","unstructured":"Di Yu W, Sun G, Li J, Xu J, Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy. Cancer Lett. 2019;452:66\u201370. https:\/\/doi.org\/10.1016\/j.canlet.2019.02.048.","journal-title":"Cancer Lett"},{"key":"1399_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/BCTT.S184710","volume":"11","author":"LA Mina","year":"2020","unstructured":"Mina LA, Lim S, Bahadur SW, Firoz AT. Immunotherapy for the Treatment of Breast Cancer: Emerging New Data. Breast Cancer: Targets Therapy. 2020;11:321\u20138. https:\/\/doi.org\/10.2147\/BCTT.S184710.","journal-title":"Breast Cancer: Targets Therapy"},{"issue":"3","key":"1399_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","volume":"70","author":"D Kwapisz","year":"2021","unstructured":"Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021;70(3):607\u201317. https:\/\/doi.org\/10.1007\/s00262-020-02736-z.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"1399_CR15","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","volume":"170","author":"JA Brown","year":"2003","unstructured":"Brown JA, et al. Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production. J Immunol. 2003;170(3):1257\u201366. https:\/\/doi.org\/10.4049\/jimmunol.170.3.1257.","journal-title":"J Immunol"},{"issue":"5256","key":"1399_CR16","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of Antitumor Immunity by CTLA-4 Blockade\u2019, Science (1979), 271(5256) 1734\u20131736, 1996. https:\/\/doi.org\/10.1126\/science.271.5256.1734","journal-title":"Science (1979)"},{"issue":"5","key":"1399_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity. 2016;44(5):989\u20131004. https:\/\/doi.org\/10.1016\/j.immuni.2016.05.001.","journal-title":"Immunity"},{"issue":"1","key":"1399_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/J.HUMPATH.2015.09.003","volume":"47","author":"A Cimino-Mathews","year":"2016","unstructured":"Cimino-Mathews A, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2016;47(1):52\u201363. https:\/\/doi.org\/10.1016\/J.HUMPATH.2015.09.003.","journal-title":"Hum Pathol"},{"issue":"4","key":"1399_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2326-6066.CIR-14-0133","volume":"3","author":"H Wimberly","year":"2015","unstructured":"Wimberly H, et al. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res. 2015;3(4):326\u201332. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0133.","journal-title":"Cancer Immunol Res"},{"key":"1399_CR20","doi-asserted-by":"publisher","first-page":"558757","DOI":"10.3389\/FIMMU.2020.558757\/TEXT","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu Q, Cheng R, Kong X, Wang Z, Fang Y, Wang J. Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data. Front Immunol. 2020;11:558757. https:\/\/doi.org\/10.3389\/FIMMU.2020.558757\/TEXT.","journal-title":"Front Immunol"},{"issue":"5","key":"1399_CR21","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/S10753-023-01830-5","volume":"46","author":"R Kern","year":"2023","unstructured":"Kern R, et al. The Expression of CTLA-4 in Breast Tumors and Tumor-Infiltrating Leukocytes Affects Patients\u2019 Systemic Inflammatory Status and Varies According to Their Molecular Subtypes. Inflammation. 2023;46(5):1639\u201352. https:\/\/doi.org\/10.1007\/S10753-023-01830-5.","journal-title":"Inflammation"},{"issue":"1","key":"1399_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/S00005-021-00618-5","volume":"69","author":"R Kern","year":"2021","unstructured":"Kern R, Panis C CTLA-4 Expression and its clinical significance in breast cancer. Arch Immunol Ther Exp. 2021;69(1):16. https:\/\/doi.org\/10.1007\/S00005-021-00618-5","journal-title":"Arch Immunol Ther Exp"},{"issue":"7","key":"1399_CR23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00262-015-1696-2","volume":"64","author":"H Yu","year":"2015","unstructured":"Yu H, Yang J, Jiao S, Li Y, Zhang W, Wang J. Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis. Cancer Immunol Immunother. 2015;64(7):853\u201360. https:\/\/doi.org\/10.1007\/s00262-015-1696-2.","journal-title":"Cancer Immunol Immunother"},{"key":"1399_CR24","doi-asserted-by":"publisher","unstructured":"Liu Q, et al. Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples. Front Immunol. 2021;12. https:\/\/doi.org\/10.3389\/fimmu.2021.599207.","DOI":"10.3389\/fimmu.2021.599207"},{"issue":"11","key":"1399_CR25","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova J, et al Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11(11):1013. https:\/\/doi.org\/10.1038\/s41419-020-03221-2.","journal-title":"Cell Death Dis"},{"issue":"18","key":"1399_CR26","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.3390\/cancers15184479","volume":"15","author":"G Angelico","year":"2023","unstructured":"Angelico G, et al. Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist\u2019s Perspective. Cancers (Basel). 2023;15(18):4479. https:\/\/doi.org\/10.3390\/cancers15184479.","journal-title":"Cancers (Basel)"},{"key":"1399_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","volume":"452","author":"W-D Yu","year":"2019","unstructured":"Yu W-D, Sun G, Li J, Xu J, Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy. Cancer Lett. 2019;452:66\u201370. https:\/\/doi.org\/10.1016\/j.canlet.2019.02.048.","journal-title":"Cancer Lett"},{"issue":"8","key":"1399_CR28","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI9872","volume":"105","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105(8):1045\u20137. https:\/\/doi.org\/10.1172\/JCI9872.","journal-title":"J Clin Invest"},{"key":"1399_CR29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.canlet.2017.01.040","volume":"400","author":"Y-L Chen","year":"2017","unstructured":"Chen Y-L, Chang M-C, Cheng W-F Metronomic chemotherapy and immunotherapy in cancer treatment. Cancer Lett. 2017;400:282\u201392. . https:\/\/doi.org\/10.1016\/j.canlet.2017.01.040.","journal-title":"Cancer Lett"},{"key":"1399_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.canlet.2016.12.018","volume":"400","author":"E Biziota","year":"2017","unstructured":"Biziota E, Mavroeidis L, Hatzimichael E, Pappas P. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. Cancer Lett. 2017;400:243\u201351. https:\/\/doi.org\/10.1016\/j.canlet.2016.12.018.","journal-title":"Cancer Lett"},{"issue":"2","key":"1399_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","volume":"358","author":"I Kareva","year":"2015","unstructured":"Kareva I, Waxman DJ, Lakka Klement G. Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 2015;358(2):100\u20136. https:\/\/doi.org\/10.1016\/j.canlet.2014.12.039.","journal-title":"Cancer Lett"},{"issue":"1","key":"1399_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41523-020-0171-1","volume":"6","author":"KA Khan","year":"2020","unstructured":"Khan KA, et al. Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. NPJ Breast Cancer. 2020;6(1):29. https:\/\/doi.org\/10.1038\/s41523-020-0171-1.","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"1399_CR33","first-page":"519","volume":"12","author":"Q Chen","year":"2020","unstructured":"Chen Q., et al. Metronomic paclitaxel improves the efficacy of PD-1 monoclonal antibodies in breast cancer by transforming the tumor immune microenvironment. Am J Transl Res. 2020;12(2):519\u201330. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32194900. Accessed: Jan. 20, 2026. [Online]. Available:.","journal-title":"Am J Transl Res"},{"issue":"6","key":"1399_CR34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2217\/imt-2022-0254","volume":"15","author":"X Zheng","year":"2023","unstructured":"Zheng X, Kuai J, Shen G. Low-Dose Metronomic Gemcitabine Pretreatments Overcome the Resistance of Breast Cancer to Immune Checkpoint Therapy. Immunotherapy. 2023;15(6):429\u201342. https:\/\/doi.org\/10.2217\/imt-2022-0254.","journal-title":"Immunotherapy"},{"issue":"6382","key":"1399_CR35","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science (1979). 2018;359(6382):1350\u20135. . https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science (1979)"},{"issue":"6","key":"1399_CR36","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro K, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717\u201326. https:\/\/doi.org\/10.1016\/S1470-2045(16)00175-3.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1399_CR37","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/ANNONC\/MDY517","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397\u2013404. https:\/\/doi.org\/10.1093\/ANNONC\/MDY517.","journal-title":"Ann Oncol"},{"issue":"3","key":"1399_CR38","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):405\u201311. https:\/\/doi.org\/10.1093\/annonc\/mdy518.","journal-title":"Ann Oncol"},{"key":"1399_CR39","doi-asserted-by":"publisher","unstructured":"Schmid P, et al. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study. Eur J Cancer. 2023;195(113393). https:\/\/doi.org\/10.1016\/J.EJCA.2023.113393.","DOI":"10.1016\/J.EJCA.2023.113393"},{"issue":"22","key":"1399_CR40","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1200\/JCO.20.02923","volume":"39","author":"AS Alva","year":"2021","unstructured":"Alva AS, et al. Pembrolizumab in Patients with Metastatic Breast Cancer with High Tumor Mutational Burden: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021;39(22):2443\u201351. https:\/\/doi.org\/10.1200\/JCO.20.02923.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1399_CR41","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.annonc.2020.01.072","volume":"31","author":"P Schmid","year":"2020","unstructured":"Schmid P, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol. 2020;31(5):569\u201381. https:\/\/doi.org\/10.1016\/j.annonc.2020.01.072.","journal-title":"Ann Oncol"},{"issue":"9","key":"1399_CR42","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMOA1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMOA1910549.","journal-title":"N Engl J Med"},{"issue":"24","key":"1399_CR43","doi-asserted-by":"publisher","first-page":"5249","DOI":"10.1158\/1078-0432.CCR-22-1110","volume":"28","author":"M Shah","year":"2022","unstructured":"Shah M, et al. FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer. Clin Cancer Res. 2022;28(24):5249\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1110.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1399_CR44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMOA2202809\/","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022;387(3):217\u201326. https:\/\/doi.org\/10.1056\/NEJMOA2202809\/. SUPPL_FILE\/NEJMOA2202809_DATA-SHARING.PDF.","journal-title":"N Engl J Med"},{"issue":"7","key":"1399_CR45","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","volume":"23","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888\u201398. https:\/\/doi.org\/10.1016\/S1470-2045(22)00290-X.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1399_CR46","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1038\/S41591-024-03249-3","volume":"30","author":"I Nederlof","year":"2024","unstructured":"Nederlof I et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial. Nat Med. 2024;30(11):3223. https:\/\/doi.org\/10.1038\/S41591-024-03249-3.","journal-title":"Nat Med"},{"issue":"1","key":"1399_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-59695-1","volume":"16","author":"R Barroso-Sousa","year":"2025","unstructured":"Barroso-Sousa R, et al. Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS). Nat Commun. 2025;16(1):1\u201313. https:\/\/doi.org\/10.1038\/s41467-025-59695-1.","journal-title":"Nat Commun"},{"issue":"2","key":"1399_CR48","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1158\/1078-0432.CCR-21-2182","volume":"28","author":"S Adams","year":"2022","unstructured":"Adams S, et al. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti\u2013CTLA-4 and Anti\u2013PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clin Cancer Res. 2022;28(2):271\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2182.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1399_CR49","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/S41591-024-03414-8","volume":"31","author":"S Loi","year":"2025","unstructured":"Loi S, et al. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat Med. 2025;31(2):433\u201341. https:\/\/doi.org\/10.1038\/S41591-024-03414-8.","journal-title":"Nat Med"},{"key":"1399_CR50","doi-asserted-by":"publisher","unstructured":"Wesolowski J, Tankiewicz-Kwedlo A, Pawlak D. Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer. Cancers (Basel). 2022;14(16). https:\/\/doi.org\/10.3390\/CANCERS14163860.","DOI":"10.3390\/CANCERS14163860"},{"issue":"8","key":"1399_CR51","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens LA, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021;32(8):983\u201393. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.355.","journal-title":"Ann Oncol"},{"issue":"8","key":"1399_CR52","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/J.ANNONC.2021.05.801","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles D, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994\u20131004. https:\/\/doi.org\/10.1016\/J.ANNONC.2021.05.801.","journal-title":"Ann Oncol"},{"issue":"10257","key":"1399_CR53","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090\u2013100. https:\/\/doi.org\/10.1016\/S0140-6736(20)31953-X.","journal-title":"Lancet"},{"issue":"7","key":"1399_CR54","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","volume":"35","author":"R Dent","year":"2024","unstructured":"Dent R, et al. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Ann Oncol. 2024;35(7):630\u201342. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.001.","journal-title":"Ann Oncol"},{"issue":"4","key":"1399_CR55","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1158\/1078-0432.CCR-23-2084","volume":"30","author":"P Schmid","year":"2024","unstructured":"Schmid P, et al. First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results. Clin Cancer Res. 2024;30(4):767\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2084.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1399_CR56","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","volume":"33","author":"S Loibl","year":"2022","unstructured":"Loibl S, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022;33(11):1149\u201358. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1940.","journal-title":"Ann Oncol"},{"key":"1399_CR57","doi-asserted-by":"publisher","unstructured":"Garber HR, et al. Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II\u2013III breast cancer. Oncotarget. 2024;15(238\u2013247). https:\/\/doi.org\/10.18632\/ONCOTARGET.28567.","DOI":"10.18632\/ONCOTARGET.28567"},{"issue":"3","key":"1399_CR58","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/S10549-017-4537-5","volume":"167","author":"LY Dirix","year":"2018","unstructured":"Dirix LY, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167(3):671\u201386. https:\/\/doi.org\/10.1007\/S10549-017-4537-5.","journal-title":"Breast Cancer Res Treat"},{"issue":"5suppl","key":"1399_CR59","doi-asserted-by":"publisher","first-page":"TPS598","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS598","volume":"38","author":"PF Conte","year":"2020","unstructured":"Conte PF, et al. Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial. J Clin Oncol. 2020;38(5suppl):TPS598\u2013598. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS598.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1399_CR60","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016.","journal-title":"Ann Oncol"},{"issue":"9","key":"1399_CR61","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1200\/OP.22.00284","volume":"18","author":"P Vikas","year":"2022","unstructured":"Vikas P, Korde LA, Somerfield MR, Hershman DL. Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncol Pract. 2022;18(9):649\u201351. https:\/\/doi.org\/10.1200\/OP.22.00284.","journal-title":"JCO Oncol Pract"},{"issue":"12","key":"1399_CR62","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer \u2606. Ann Oncol. 2021;32(12):1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","journal-title":"Ann Oncol"},{"key":"1399_CR63","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/ANNUREV.IMMUNOL.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704. https:\/\/doi.org\/10.1146\/ANNUREV.IMMUNOL.26.021607.090331.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"1399_CR64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/J.1600-065X.2010.00923.X","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236(1):219\u201342. https:\/\/doi.org\/10.1111\/J.1600-065X.2010.00923.X.","journal-title":"Immunol Rev"},{"key":"1399_CR65","doi-asserted-by":"publisher","unstructured":"Jin M, et al. PD-1\/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies. Mol Cancer. 2024;23(1). https:\/\/doi.org\/10.1186\/S12943-024-02176-8.","DOI":"10.1186\/S12943-024-02176-8"},{"issue":"13","key":"1399_CR66","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1158\/1078-0432.CCR-10-0505","volume":"16","author":"RH Vonderheide","year":"2010","unstructured":"Vonderheide RH, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res. 2010;16(13):3485\u201394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0505.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1399_CR67","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, et al Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970","journal-title":"N Engl J Med"},{"key":"1399_CR68","doi-asserted-by":"publisher","unstructured":"Hu G, Wang S, Wang S, Ding Q, Huang L. LAG-3\u2009+\u2009tumor-infiltrating lymphocytes ameliorates overall survival in triple-negative breast cancer patients. Front Oncol. 2023;12(986903). https:\/\/doi.org\/10.3389\/FONC.2022.986903\/BIBTEX.","DOI":"10.3389\/FONC.2022.986903\/BIBTEX"},{"key":"1399_CR69","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/S41568-021-00346-0","volume":"21","author":"M van der Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJM, Bhardwaj N Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21:360\u201378. https:\/\/doi.org\/10.1038\/S41568-021-00346-0","journal-title":"Nat Rev Cancer"},{"key":"1399_CR70","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2021.10.027","volume":"160","author":"C Corti","year":"2022","unstructured":"Corti C, Giachetti PPMB, Eggermont AMM, Delaloge S, Curigliano G. Therapeutic vaccines for breast cancer: Has the time finally come? Eur J Cancer. 2022;160:150\u201374. https:\/\/doi.org\/10.1016\/j.ejca.2021.10.027.","journal-title":"Eur J Cancer"},{"issue":"7","key":"1399_CR71","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","volume":"25","author":"N Zaidi","year":"2025","unstructured":"Zaidi N, Jaffee EM, Yarchoan M. Recent advances in therapeutic cancer vaccines. Nat Rev Cancer. 2025;25(7):517\u201333. https:\/\/doi.org\/10.1038\/s41568-025-00820-z.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1399_CR72","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/JSO.21723","volume":"105","author":"KS Clive","year":"2012","unstructured":"Clive KS, et al. The GP2 peptide: A HER2\/neu-based breast cancer vaccine. J Surg Oncol. 2012;105(5):452\u20138. https:\/\/doi.org\/10.1002\/JSO.21723.","journal-title":"J Surg Oncol"},{"issue":"52","key":"1399_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000036793","volume":"102","author":"G Olatunji","year":"2023","unstructured":"Olatunji G, et al. AE37 HER2-targeted vaccine in the prevention of breast cancer recurrence: A mini narrative review of current evidence. Medicine. 2023;102(52):e367931. https:\/\/doi.org\/10.1097\/MD.0000000000036793","journal-title":"Medicine"},{"issue":"5","key":"1399_CR74","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2217\/IMT.14.22","volume":"6","author":"EJ Schneble","year":"2014","unstructured":"Schneble EJ, et al. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax\u2122) in breast cancer patients at risk for recurrence: Correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519\u201331. https:\/\/doi.org\/10.2217\/IMT.14.22.","journal-title":"Immunotherapy"},{"key":"1399_CR75","doi-asserted-by":"publisher","unstructured":"Lee SB, et al. Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention. NPJ Precis Oncol. 2023;7(1). https:\/\/doi.org\/10.1038\/S41698-023-00461-1.","DOI":"10.1038\/S41698-023-00461-1"},{"issue":"16suppl","key":"1399_CR76","doi-asserted-by":"publisher","first-page":"TPS1112","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1112","volume":"41","author":"S Gandhi","year":"2023","unstructured":"Gandhi S, et al. Phase IIa study of \u03b1DC1 vaccines targeting HER2\/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2 + breast cancer. J Clin Oncol. 2023;41(16suppl):TPS1112\u20131112. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS1112.","journal-title":"J Clin Oncol"},{"key":"1399_CR77","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/J.JCONREL.2022.07.036","volume":"349","author":"F Davodabadi","year":"2022","unstructured":"Davodabadi F, Sarhadi M, Arabpour J, Sargazi S, Rahdar A. D\u00edez-Pascual, \u2018Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches\u2019. J Controlled Release. 2022;349:844\u201375. https:\/\/doi.org\/10.1016\/J.JCONREL.2022.07.036.","journal-title":"J Controlled Release"},{"key":"1399_CR78","doi-asserted-by":"publisher","first-page":"9749363","DOI":"10.1155\/2022\/9749363","volume":"2022","author":"N Abd-Aziz","year":"2022","unstructured":"Abd-Aziz N, Poh CL. Development of peptide-based vaccines for cancer. J. Oncol., 2022;2022:9749363. https:\/\/doi.org\/10.1155\/2022\/9749363","journal-title":"J Oncol"},{"issue":"2","key":"1399_CR79","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1586\/ERV.10.167","volume":"10","author":"LC Benavides","year":"2011","unstructured":"Benavides LC, et al. Comparison of different HER2\/neu vaccines in adjuvant breast cancer trials: Implications for dosing of peptide vaccines. Expert Rev Vaccines. 2011;10(2):201\u201310. https:\/\/doi.org\/10.1586\/ERV.10.167.","journal-title":"Expert Rev Vaccines"},{"issue":"11","key":"1399_CR80","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1158\/1078-0432.CCR-19-2741","volume":"26","author":"GT Clifton","year":"2020","unstructured":"Clifton GT, et al. Results of a Randomized Phase IIb Trial of Nelipepimut-S \u00fe Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer. Clin Cancer Res. 2020;26(11):2515\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2741.","journal-title":"Clin Cancer Res"},{"issue":"16suppl","key":"1399_CR81","doi-asserted-by":"publisher","first-page":"TPS1125","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1125","volume":"40","author":"GT Budd","year":"2022","unstructured":"Budd GT, et al. Phase I trial of an alpha-lactalbumin vaccine in patients with moderate- to high-risk operable triple-negative breast cancer (TNBC). J Clin Oncol. 2022;40(16suppl):TPS1125\u20131125. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS1125.","journal-title":"J Clin Oncol"},{"key":"1399_CR82","doi-asserted-by":"publisher","unstructured":"Huang CS, et al. Globo H-KLH vaccine adagloxad simolenin (OBI-822)\/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. J Immunother Cancer. 2020;8(2). https:\/\/doi.org\/10.1136\/JITC-2019-000342.","DOI":"10.1136\/JITC-2019-000342"},{"key":"1399_CR83","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-3-319-42934-2_5","volume":"209","author":"K Fiedler","year":"2016","unstructured":"Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R. mRNA cancer vaccines. Recent Results Cancer Res. 2016;209:61\u201385. https:\/\/doi.org\/10.1007\/978-3-319-42934-2_5.","journal-title":"Recent Results Cancer Res"},{"issue":"1","key":"1399_CR84","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/JAMAONCOL.2022.5143","volume":"9","author":"ML (nora) Disis","year":"2023","unstructured":"(nora) Disis ML, et al. Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients with Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 2023;9(1):71\u20138. https:\/\/doi.org\/10.1001\/JAMAONCOL.2022.5143.","journal-title":"JAMA Oncol"},{"key":"1399_CR85","doi-asserted-by":"publisher","unstructured":"Koido S. Dendritic-tumor fusion cell-based cancer vaccines. Int J Mol Sci. 2016;17(6). https:\/\/doi.org\/10.3390\/IJMS17060828.","DOI":"10.3390\/IJMS17060828"},{"key":"1399_CR86","doi-asserted-by":"publisher","unstructured":"Hou W, Yi C, Zhu H. Predictive biomarkers of colon cancer immunotherapy: Present and future. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/FIMMU.2022.1032314.","DOI":"10.3389\/FIMMU.2022.1032314"},{"key":"1399_CR87","doi-asserted-by":"publisher","unstructured":"Jin Y, et al. Prognostic Impact of Memory CD8(+) T Cells on Immunotherapy in Human Cancers: A Systematic Review and Meta-Analysis. Front Oncol. 2021;11(698076). https:\/\/doi.org\/10.3389\/fonc.2021.698076.","DOI":"10.3389\/fonc.2021.698076"},{"issue":"1","key":"1399_CR88","doi-asserted-by":"publisher","first-page":"10396","DOI":"10.1038\/s41598-024-60819-8","volume":"14","author":"MM Noblejas-L\u00f3pez","year":"2024","unstructured":"Noblejas-L\u00f3pez MM, Garc\u00eda-Gil E, P\u00e9rez-Segura P, Pandiella A, Gy\u0151rffy B, Oca\u00f1a A. T-reg transcriptomic signatures identify response to check-point inhibitors. Sci Rep. 2024;14(1):10396 https:\/\/doi.org\/10.1038\/s41598-024-60819-8","journal-title":"Sci Rep"},{"key":"1399_CR89","doi-asserted-by":"publisher","unstructured":"Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/FIMMU.2023.1212476.","DOI":"10.3389\/FIMMU.2023.1212476"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01399-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01399-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01399-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:41:11Z","timestamp":1782376871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01399-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1399"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01399-9","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"33"}}